The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Open accessAbstract
In the last 10 years a deeper understanding of the immune landscape of cancers, including immune-evasion processes, has allowed the development of a new class of agents. The re-activation of host anti-tumor immune response, offers the potential for long-term survival benefit in a portion of patients with thoracic malignancies. The advent of programmed death-1 (PD-1) / programmed death ligand-1 (PD-L1) immune-checkpoint inhibitors (ICI), both as single agents and in combination with chemotherapy, and more recently combination of ICI, anti-PD1 and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, have led to breakthrough therapeutic advances for patients with advanced non-small cell lung cancer (NSCLC) and to a lesser extent, patients with small cell lung cancer (SCLC). Encouraging activity has recently emerged in pre-treated patients with thymic carcinoma. Conversely in malignant pleural mesothelioma, pivotal positive signs of activity have not been fully confirmed in randomized trials. The additive effects of chemoradiation and immunotherapy suggested intriguing potential for therapeutic synergy with combination strategies. This has led to the introduction of ICI consolidation therapy in stage III NSCLC creating a platform for future therapeutic developments in earlier stage disease. Despite the definitive clinical benefit observed with ICI, primary and acquired resistance represent well-known biological phenomena, which may significantly impact the therapeutic efficacy of these agents. The development of innovative strategies to overcome ICI resistance, standardization of new patterns of ICI progression, identification of predictive biomarkers of response, optimal treatment duration, and characterization of ICI efficacy in special populations, represent crucial issues to be adequately addressed, with the aim of improving the therapeutic benefit of ICI in patients with thoracic malignancies. In the current paper, an international panel of experts in the field of thoracic malignancies discussed these topics, evaluating currently available scientific evidence, with the final aim of providing clinical recommendations, which may guide oncologists in their current practice, and elucidate future treatment strategies and research priorities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 3×
“In the same year, Sivan et al.245 reported similar findings in anti–PD-L1 settings.”
BackgroundResultInfluentialComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 2×
“In another study, Vétizou et al.(244) verified that Bacteroides thetaiotaomicron or Bacteroides fragilis was associated with the efficacy of CTLA-4 blockade both in mice and humans.”
Result
Cited by
Leader, A. M., Grout, J. A., Maier, B. B., Nabet, B. Y., Park, M. D., Tabachnikova, A., Chang, C., Walker, L., Lansky, A., Le Berichel, J., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.009 · Cited by 365
Rothschild, S. I., Zippelius, A., Eboulet, E. I., Savic Prince, S., Betticher, D., Bettini, A., Früh, M., Joerger, M., Lardinois, D., Gelpke, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00276 · Cited by 333
Tsamakis, K., Gavriatopoulou, M., Schizas, D., Stravodimou, A., Mougkou, A., Tsiptsios, D., Sioulas, V., Spartalis, E., Sioulas, A., Tsamakis, C., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11599 · Cited by 164
An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy
Feng, M., Cui, H., Tu, W., Li, L., Gao, Y., Chen, L., Li, D., Chen, X., Xu, F., Zhou, C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.975381 · Cited by 37
“The poor efficacy of immunotherapy for some tumors has brought great challenges to clinical treatment (Remon et al., 2020).”
Background
Metadata
- Authors
- Remon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., Kubota, K., Lu, S., Mezquita, L., Paz-Ares, L., Popat, S., Schalper, K. A., Skoulidis, F., Reck, M., Adjei, A. A., & Scagliotti, G. V.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 15
- Issue
- 6
- Pages
- 914-947
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3010741030
- Cited by
- 169
- References
- 70
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. https://app.cochat.ai/papers/10.1016/j.jtho.2020.03.006
- The paper
- Remon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., Kubota, K., Lu, S., Mezquita, L., Paz-Ares, L., Popat, S., Schalper, K. A., Skoulidis, F., Reck, M., Adjei, A. A., & Scagliotti, G. V. (2020). Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.03.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.